Jenburkt Pharmaceuticals Ltd saw its shareholding pattern shift as Counter Cyclical Investments Private Limited crossed the 5% threshold. The portfolio manager acquired 326 shares in the open market, lifting its aggregate holding to 220,931 shares, or 5.01% of the total paid-up capital.

The transaction occurred on October 9, 2026. Prior to this acquisition, Counter Cyclical Investments held 220,605 shares, representing 4.99% of the company's equity. The incremental purchase of just 326 shares was sufficient to push the entity across the mandatory disclosure limit defined by SEBI regulations.

Regulatory Disclosure Details

The acquisition was executed by Counter Cyclical Investments Private Limited acting as a Portfolio Manager for its clients. The disclosure was filed under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquirer is not part of the promoter or promoter group.

What the Numbers Show

The data highlights a critical inflection point in regulatory reporting. A marginal increase of 0.01% in equity ownership triggered a mandatory public disclosure. This underscores how minor open market purchases can significantly alter the transparency obligations for institutional investors once they approach the 5% mark. The total diluted share capital remained unchanged at 4,413,300 shares before and after the transaction.

Jenburkt Pharmaceuticals Limited equity shares have been admitted to the National Stock Exchange of India Limited (NSE) under the “Permitted to Trade” category. This admission is effective from August 17, 2026, following a circular issued by the exchange.

The company confirmed that it did not apply for this listing. The shares remain primarily listed on the BSE Limited. The inclusion on NSE is automatic under the specified category, allowing trading without a formal application from the issuer.

Regulatory context and disclosure

The intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Jenburkt Pharmaceuticals stated that it became aware of the development through NSE Circular No. NSE/CML/75748 dated August 14, 2026.

The company noted that no separate communication or intimation regarding this admission was received directly from the NSE prior to the public circular. The disclosure was made subsequently for the information of shareholders and stakeholders.

Key details of the admission

This move enhances liquidity options for investors by making the shares accessible on the NSE platform, although the primary regulatory obligations and listing status remain anchored with BSE.